Key statistics
On Thursday, Lipocine Inc (LPCN:NAQ) closed at 5.00, 110.09% above the 52 week low of 2.38 set on Nov 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.71 |
---|---|
High | 5.15 |
Low | 4.71 |
Bid | 3.83 |
Offer | 5.67 |
Previous close | 4.71 |
Average volume | 21.77k |
---|---|
Shares outstanding | 5.35m |
Free float | 5.19m |
P/E (TTM) | -- |
Market cap | 25.19m USD |
EPS (TTM) | -0.7626 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 20:54 GMT.
More ▼
- Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
- Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024
- Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
- Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
- Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
- Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
- Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference
- Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
- Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
More ▼